To understand why METTL3 has attracted such intense scrutiny, it helps to start with the chemistry. N6-methyladenosine is the most abundant internal chemical modification found in messenger RNA across eukaryotic cells, and it is installed and removed dynamically by dedicated enzyme complexes. METTL3 functions as the chief catalytic subunit of the methyltransferase complex, working alongside METTL14, which provides structural support, and accessory factors such as WT1-associated protein, VIRMA/KIAA1429, RBM15 and ZC3H13, which help target the complex to specific RNA substrates. The review details METTL3’s modular architecture: a central methyltransferase domain that binds the universal methyl donor S-adenosylmethionine, a zinc finger domain and a leading helix that contribute to substrate recognition, and a nuclear localization signal that governs where in the cell the protein operates. This structural organization allows METTL3 to deposit methyl marks onto thousands of RNA transcripts, altering their stability, translation efficiency, splicing and export without changing the underlying genetic sequence.

Because m6A methylation acts post-transcriptionally, it gives cancer cells a rapid and reversible way to reprogram gene expression. The review documents how METTL3 expression is itself regulated by an array of upstream signals, including cigarette smoke condensate in lung cancers, lactylation of the histone mark H3K18 in pancreatic ductal adenocarcinoma, the transcription factor Yin-yang 1, the hepatitis B X-interacting protein in hepatoblastoma, and the peptidyl prolyl isomerase PIN1. Once elevated, METTL3 methylates transcripts encoding drivers of proliferation, invasion and metabolic adaptation in malignancies ranging from acute myeloid leukemia and chronic myeloid leukemia to pancreatic, colorectal, gastric and esophageal cancers, hepatocellular carcinoma, glioblastoma, bladder cancer, ovarian cancer, prostate cancer, osteosarcoma and lung adenocarcinoma. In leukemia in particular, pharmacological inhibition of METTL3 has emerged as an active therapeutic strategy, with experimental inhibitors demonstrating that the enzyme is a druggable target rather than an incidental marker.

The most consequential portion of the review, however, concerns tumor immune escape, the process by which malignant cells avoid recognition and destruction by cytotoxic T lymphocytes, natural killer cells and other immune effectors. The authors argue that METTL3 operates along two parallel routes. The first is intrinsic: within tumor cells, METTL3-mediated methylation of specific transcripts triggers metabolic reprogramming that changes what nutrients the tumor consumes and what metabolites it releases into its surroundings. In several cancer types, METTL3 upregulates glycolytic enzymes such as hexokinase 2, intensifying aerobic glycolysis and depleting glucose from the microenvironment while flooding it with lactate and other immunosuppressive metabolites. In hepatocellular carcinoma associated with non-alcoholic fatty liver disease, METTL3 has been linked through the SREBP cleavage activating protein to lipid metabolic shifts that further distort immune signaling. These metabolic alterations do more than feed the tumor; they create a biochemical landscape in which infiltrating lymphocytes struggle to maintain their effector functions.

The second route is extrinsic and centers on the functional remodeling of tumor-infiltrating immune cells themselves. The review synthesizes evidence that METTL3 activity in macrophages skews these cells toward a tumor-associated, pro-tumoral phenotype, in part by methylating transcripts tied to the complement receptor C5aR1 and other polarization regulators. In myeloid-derived suppressor cells, METTL3-dependent methylation enhances immunosuppressive output, including the catabolism that generates kynurenine, a metabolite that acts on the N-methyl-D-aspartate receptor and other targets to dampen T-cell responses. Dendritic cells, the professional antigen-presenting cells that ignite anti-tumor T-cell immunity, also fall under METTL3’s influence, with methylation of transcripts governing maturation and interferon signaling impairing their ability to present tumor-associated antigens. Even regulatory T cells, the immune system’s own brakes, appear subject to METTL3-controlled tuning, which can tilt the balance of the tumor immune microenvironment further toward suppression.

Immune checkpoint blockade, the class of therapies that includes antibodies against PD-1 and its ligand PD-L1, has transformed treatment for many cancers but fails in a majority of patients. The review makes the case that METTL3 is deeply entangled with this variability. In lung adenocarcinoma, METTL3-mediated methylation influences splicing factors such as serine-arginine protein kinase 1, affecting PD-L1 expression and thereby the tumor’s visibility to checkpoint inhibitors. In melanoma and other models, elevated METTL3 in tumor cells has been associated with reduced interferon-gamma responsiveness and diminished recruitment of cytotoxic T lymphocytes, whereas loss of METTL3 can restore inflammatory chemokine production and sensitize tumors to anti-PD-1 therapy. Conversely, METTL3 activity within T cells themselves regulates their differentiation, integrin beta 1-mediated trafficking, granzyme B production and persistence, meaning that the same enzyme can either undermine or support immunotherapy depending on which cell compartment is examined. This cell-type-specific duality, the authors emphasize, is precisely why a systems-level understanding of the METTL3 network is needed before the enzyme can be safely targeted in combination regimens.

The clinical dimension of the review extends to biomarker discovery. Across multiple tumor types, METTL3 expression profiles correlate with disease stage, immune infiltration patterns, immune checkpoint molecule abundance and patient survival, suggesting that METTL3 levels in tumor biopsies could one day help stratify patients for immunotherapy or identify those likely to experience hyperprogression. The authors also survey emerging therapeutic approaches beyond small-molecule catalytic inhibitors, including RNA-targeted strategies such as antisense oligonucleotides and targeted protein degradation, as well as rational combinations that pair METTL3 inhibition with immune checkpoint blockade, metabolic interventions or epigenetic drugs. The concept of topical immune modulation, in which RNA-modification biology is exploited to reprogram immune cells locally within the tumor, features among the forward-looking therapeutic ideas discussed.

Yet the review is equally candid about the gaps that remain. The complete molecular network connecting METTL3 to tumor immune escape has not been systematically mapped, and many of the individual methylated transcripts responsible for the phenotypes described above have been characterized only in isolation. It is not always clear whether METTL3’s effects on immunity are direct, mediated through methylation of immune-regulatory transcripts, or indirect, secondary to its influence on tumor metabolism and growth. Context dependence complicates the picture further: METTL3 appears to act as an oncogene in several cancers but has been reported to exert tumor-suppressive effects in others, and its activity in immune cells can either restrain or promote anti-tumor responses depending on the cell type and disease setting. Resolving these contradictions, the authors argue, will require single-cell multi-omics approaches that can trace m6A deposition, transcript output and immune phenotype simultaneously at cellular resolution in human tumors.

The overarching message is that METTL3 should be viewed as a critical molecular hub bridging the intrinsic properties of cancer cells and the immune responses of the surrounding microenvironment. As the most prevalent internal RNA modification in eukaryotes, m6A methylation offers tumors a fast, flexible and reversible layer of gene control, and METTL3 is the enzyme that wields it. Whether delivered as a standalone epitranscriptomic therapy or woven into combination strategies with checkpoint inhibitors and metabolic drugs, precise targeting of METTL3 represents a highly promising anti-tumor frontier. The authors caution that translating that promise into clinical benefit will depend on refined dissection of the regulatory network governing tumor immune escape and on the development of highly specific agents that can reach the right cells at the right time. For now, the review consolidates a rapidly growing literature into a coherent framework, positioning the RNA methyltransferase that was once studied as a matter of basic biochemistry at the center of the fight against cancer’s ability to hide.

Subject of Research: The role of the m6A RNA methyltransferase METTL3 in tumor immune escape and cancer treatment

Article Title: Methyltransferase-like 3: structure, biological function and role in tumor immune escape and treatment

Article References: Liu, G., Zhu, Y., Zhang, J., Wu, J., Liao, M., Zhao, J., Guo, M., & Xu, L. (2026). Methyltransferase-like 3: structure, biological function and role in tumor immune escape and treatment. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08960-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08960-y

Keywords: METTL3, m6A methylation, tumor immune escape, epitranscriptomics, RNA modification, tumor microenvironment, immune checkpoint blockade, metabolic reprogramming, immunotherapy, cancer epigenetics, tumor-associated macrophages, PD-L1

Cancer cells are notorious for their relentless growth and survival under adverse conditions such as nutrient scarcity and hypoxia. To manage these hostile microenvironments, they activate a cellular survival mechanism known as the integrated stress response (ISR). This pathway adapts cellular functions to stressors and is crucial for cancer progression. At the heart of ISR activation is the transcription factor Activating Transcription Factor 4 (ATF4), which orchestrates the expression of numerous genes that collectively enhance cancer cell survival, metabolism, and proliferation under stress.

The NYU Langone research team focused on the relationship between ISR and immune evasion, delving into how ATF4 influences tumor-immune interactions. Their findings revealed that ATF4 stimulates the secretion of LCN2, a small soluble protein, which is secreted outside the cancer cells and plays a pivotal role in subverting the immune response. LCN2 works by modulating the behavior of macrophages—immune cells abundant in the tumor microenvironment—shifting them towards an immunosuppressive phenotype that actively excludes cytotoxic T cells, which are essential for tumor eradication.

This immunosuppressive shift orchestrated by LCN2 essentially builds a protective barrier, preventing immune cells from penetrating the tumor mass and attacking malignant cells. Unlike ATF4, which functions intracellularly and is thus challenging to target pharmacologically, LCN2 exists in the extracellular space where it is more accessible to therapeutic intervention. The researchers harnessed this feature to develop an antibody that neutralizes LCN2, effectively disarming its immune-suppressive capabilities.

Preclinical trials in mouse models of lung and pancreatic cancers demonstrated that blocking LCN2 not only halted tumor progression but also facilitated a resurgence of immune cell infiltration, especially reactivating the tumor-killing T cells. These results were even more compelling when the anti-LCN2 antibody was combined with existing immunotherapies, significantly prolonging survival in aggressive cancer models. This synergistic effect underscores the potential for LCN2-targeted therapies to overcome resistance mechanisms that have limited the efficacy of conventional immune checkpoint inhibitors.

Further substantiating the clinical relevance, tumor sample analyses from over a hundred lung cancer patients and several dozen pancreatic cancer patients showed a clear correlation between elevated LCN2 levels and poorer survival outcomes. Patients exhibiting high LCN2 expression had a median survival rate markedly lower than those with minimal expression, suggesting that LCN2 might serve as a prognostic biomarker and a determinant of immunotherapy responsiveness.

The mechanistic insight into how stressed cancer cells enlist LCN2 to manipulate the immune microenvironment opens a novel front in oncology research. It shifts the paradigm from solely focusing on tumor cells to considering how cancer-related stress pathways influence immune cell behavior, particularly macrophages. Understanding this crosstalk is essential for designing interventions that restore immune surveillance and enhance the effectiveness of immunotherapies.

The study was spearheaded by Dr. Thales Papagiannakopoulos and Dr. Shohei Koide, experts in pathology and molecular pharmacology, respectively. They emphasized that while their current research centered on lung and pancreatic cancers, the involvement of ISR and LCN2 in immune evasion could be a broader phenomenon applicable to various cancer types that presently resist immunotherapy. Their ongoing work aims to investigate this possibility, potentially extending the therapeutic benefits of LCN2 inhibition.

What sets this discovery apart is the dual advantage of targeting LCN2: it not only disrupts a key immune escape mechanism but also sensitizes tumors to existing immunotherapeutic agents. This dual-attack strategy may pave the way for personalized cancer treatments that adapt to the tumor’s molecular stress profile, thwarting its ability to hide from immune detection.

The implications of these findings extend beyond therapeutics into the realm of cancer diagnostics. LCN2 levels in tumors could become part of the diagnostic arsenal to stratify patients according to their likelihood of responding to immunotherapies. Such precision medicine approaches are vital in optimizing clinical outcomes and avoiding unnecessary treatments.

Funding for this pivotal research came from multiple National Institutes of Health grants, the American Cancer Society, the National Science Foundation, and several philanthropic organizations, underscoring the high priority and collaborative nature of cancer research. The authors have declared relationships with various pharmaceutical and biotech companies, managed in accordance with institutional policies to ensure scientific integrity.

NYU Langone Health’s integrated system of research, clinical care, and education provides a fertile environment for such high-impact studies, reflecting its standing as a leading academic medical center. The Perlmutter Cancer Center, central to this research, continues to push the boundaries of knowledge to develop next-generation cancer therapies.

As the oncology community digests these findings, the future looks promising for exploiting the ISR-LCN2 axis to unlock tumors from their immunosuppressive cocoons. This study not only advances scientific understanding but also inspires a new wave of therapeutic innovations aimed at tipping the balance in favor of the immune system and improving survival for patients battling some of the most formidable cancers.

Subject of Research: Human tissue samples

Article Title: ‘The integrated stress response promotes immune evasion through lipocalin 2’

News Publication Date: 18-Feb-2026

Web References:
DOI Link to Article

Keywords: Cancer, Transcription factors

For years, glycosylation has been recognized as a pivotal modulator of protein localization and function, influencing everything from cell-cell communication to immune recognition. Unexpectedly, this research identifies that small RNAs themselves undergo N-glycosylation at a unique RNA base, 3-(3-amino-3-carboxypropyl) uridine (acp³U). This finding challenges the traditional dogma that RNA modifications merely Fine-tune RNA stability or translation, instead assigning a critical, previously undiscovered immunomodulatory function to RNA glycosylation.

The team’s experiments reveal that when these N-glycans are enzymatically removed from glycoRNAs isolated from both human and mouse cell cultures as well as from circulating extracellular compartments, a robust innate immune activation ensues. This response is characterized by a surge in type I interferons, molecules central to antiviral defenses and inflammatory pathways. Strikingly, this immune activation relies heavily on Toll-like receptor 3 (TLR3) and Toll-like receptor 7 (TLR7), classical sensors of viral RNA located within the endosomal compartment.

Delving deeper, the researchers probed the functional consequences of RNA glycosylation in the context of apoptotic cell clearance, a physiological process crucial for tissue homeostasis. Apoptotic cells expose small glycoRNAs on their surfaces; these N-glycans effectively cloak the immunogenic acp³U modification on the RNA, preventing recognition by efferocytes—specialized phagocytic cells tasked with engulfing dead cells without provoking inflammation. When N-glycans are removed, these apoptotic cells inappropriately activate endosomal RNA sensors, leading to unwarranted inflammatory signaling that could contribute to autoimmune pathogenesis.

Mechanistically, the study establishes that N-glycans act as a biochemical barrier, shielding the hypermodified uracil base acp³U on glycoRNAs from detection by innate immune receptors. The immunostimulatory potential of acp³U becomes unmasked only upon de-N-glycosylation, suggesting a direct interplay between RNA glycosylation status and immune sensor accessibility. This molecular camouflage elegantly explains how glycoRNAs can localize to cellular surfaces and navigate the endosomal environment without precipitating autoinflammatory responses.

A critical validation of this mechanism comes from the genetic deletion of DTWD2, an enzyme responsible for the synthesis of the acp³U modification. Cells lacking DTWD2 fail to activate innate immune signaling in response to de-N-glycosylated RNAs and apoptotic cells, underscoring that acp³U is indispensable for immune recognition in this context. Furthermore, synthetic RNAs engineered to contain acp³U and lacking N-glycans are sufficient to potently stimulate innate immune pathways, confirming the causative role of this RNA base modification in immune activation.

Beyond deepening fundamental RNA biology, these findings have profound implications for understanding and potentially manipulating immune evasion mechanisms. The discovery of RNA N-glycosylation as an immunological “off switch” that prevents self-RNA from triggering innate sensors reveals a molecular safeguard against autoimmune inflammation. Dysregulation of this process may underlie pathologies where apoptosis and immune clearance balance is disturbed, such as systemic lupus erythematosus and other chronic inflammatory diseases.

The existence of glycoRNAs on cell surfaces and in extracellular compartments adds a new layer of complexity to the landscape of glycosylation and innate immunity. Not only proteins but also small RNAs are subject to sophisticated post-transcriptional modifications that dictate their immunological fate. This paradigm shift forces a reconsideration of how RNA modifications and glycosylation collectively shape host defense and self-tolerance.

From a therapeutic perspective, the pathway identified offers exciting avenues for intervention. Targeting the enzymatic machinery responsible for RNA glycosylation or the recognition of acp³U-modified RNA could yield novel strategies to modulate immune responses. For instance, suppressing aberrant immune activation in autoimmunity or enhancing antiviral immunity through controlled exposure of acp³U-containing RNAs might become feasible.

Moreover, the involvement of Toll-like receptors 3 and 7 situates this glycoRNA-centric mechanism in the broader context of viral sensing and innate immune surveillance. Since these receptors detect viral RNA patterns, the masking of endogenous RNA signatures by N-glycans prevents the immune system from mistaking self for non-self. This has striking evolutionary and biomedical relevance, highlighting a refined molecular interplay between host and pathogen signals.

In summary, this pioneering research delineates a previously unappreciated role of RNA N-glycosylation in immune regulation. By concealing an immunogenic modified base, glycoRNAs evade innate immune detection and facilitate silent apoptotic cell clearance, preserving tissue homeostasis. This advance not only expands the known functions of glycosylation and RNA modifications but also sets the stage for novel insights into immunity, inflammation, and potential therapeutic innovation.

The convergence of RNA biology, glycobiology, and immunology exemplified in this study underscores the multidimensional nature of cellular regulation. Future research will undoubtedly explore the full repertoire of glycoRNA modifications, their enzymatic regulators, and their impact across diverse physiological and pathological contexts. This breakthrough reinvigorates the quest to understand how chemical modifications sculpt biomolecule function and immune interactions at the most fundamental levels.

Subject of Research: N-glycosylation of small RNAs and its role in innate immune evasion and apoptotic cell clearance.

Article Title: RNA N-glycosylation enables immune evasion and homeostatic efferocytosis.

Article References:
Graziano, V.R., Porat, J., Ah Kioon, M.D. et al. RNA N-glycosylation enables immune evasion and homeostatic efferocytosis. Nature (2025). https://doi.org/10.1038/s41586-025-09310-6

Image Credits: AI Generated

This pioneering research shifts the focus beyond biochemical communication between cancer cells and immune defenses, illuminating how the mechanical characteristics of tumor tissue itself influence disease progression. The softness or stiffness of the extracellular matrix surrounding tumor cells—historically underappreciated in oncology—has emerged as a pivotal factor dictating immune cell infiltration and activity. Specifically, the study highlights that a softer tumor microenvironment fosters a form of immunosuppression, enabling malignant cells to evade immune surveillance and facilitating faster tumor growth.

Using fresh breast cancer tissue samples directly obtained from patients during surgery, the research team was able to circumvent the limitations of traditional experimental models that rely on cultured cells or animal subjects. This approach allowed a more faithful representation of tumor behavior in its native context. It was observed that within these softer matrices, immune cells become functionally inhibited through a signaling cascade involving cyclooxygenase (COX) enzymes and fibroblast growth factor 2 (FGF2). These molecular signals contribute to a local immune microenvironment incapable of mounting an effective anti-tumor response.

The involvement of COX-FGF2 signaling in the mechanical modulation of immune cells is a groundbreaking discovery that links biomechanical properties to biochemical immunosuppressive pathways. This finding not only elucidates a novel axis of tumor immune evasion but also identifies potential molecular targets for therapeutic intervention. By modulating this signaling pathway, it may be possible to restore immune competence within soft tumor niches and enhance the efficacy of existing immunotherapies.

Importantly, these revelations carry profound clinical implications. The variability in tissue stiffness among breast cancer patients could serve as a biomarker to predict which individuals are less likely to benefit from immunotherapy. This enables a more rational selection of treatment strategies, sparing non-responsive patients from unnecessary side effects and focusing resources on therapies better suited to their tumor’s biomechanical profile.

The Finnish collaboration behind this research is distinguished by its exceptional access to high-quality human tissue specimens, collected through a unique integration of the University of Helsinki, HUS Helsinki University Hospital, and Kymenlaakso Health and Social Services. This seamless pipeline from operating theaters to the laboratory permits the study of live, patient-derived tumors, providing unparalleled insights into the complex interplays governing cancer progression in humans rather than animal surrogates.

Such collaborative infrastructure is rare on a global scale, and the project has piqued international interest among cancer researchers eager to replicate this model. The Finnish research environment, characterized by this synergy between clinical practice and basic science, exemplifies how integrated healthcare and academic partnerships can accelerate translational medicine.

Another core element of this study’s success is the generosity of participating patients, who consent to donate surplus tumor tissue for research. Their contributions are invaluable, offering scientists raw material for discoveries that may lead to improved therapies and ultimately, better prognoses for future patients. This patient-driven aspect epitomizes the ethical foundation of modern biomedical research.

Looking forward, the team’s findings open new avenues for therapeutic development. Drugs specifically targeting the COX-FGF2 signaling pathway or agents capable of modifying the mechanical microenvironment hold promise as adjuncts to current immunotherapies. These innovations could potentially convert immunologically “cold” tumors, resistant to immune attack, into “hot” tumors, which are more vulnerable to immune system eradication.

Moreover, this study underscores the necessity of considering mechanical forces and tissue physicality in cancer biology, domains historically overshadowed by genetic and molecular analyses. Integrating biomechanical perspectives into oncology could yield a more holistic understanding of tumor ecosystems and their vulnerabilities.

Ultimately, the enhanced comprehension of how soft matrices impair immune function within tumors heralds a new frontier in cancer treatment. It advocates for more nuanced diagnostic tools that assess tissue stiffness alongside genetic profiling, enabling precision oncology to reach its full potential. As immunotherapy continues to evolve, such multidisciplinary insights will be crucial for overcoming current limitations and expanding benefits to a broader patient population.

The innovative methods and profound discoveries emanating from this Finnish research embody the future of personalized cancer care. By unraveling the interconnectedness of physical tissue properties and immune suppression, researchers are poised to develop more effective, targeted interventions that could transform outcomes for breast cancer patients worldwide.

—

Subject of Research: Human tissue samples

Article Title: Soft matrix promotes immunosuppression in tumor-resident immune cells via COX-FGF2 signaling

News Publication Date: 27-May-2025

Web References: http://dx.doi.org/10.1038/s41467-025-60092-x

Image Credits: Pauliina Munne

Keywords: Immunotherapy, breast cancer, tumor microenvironment, tissue stiffness, immune suppression, COX-FGF2 signaling, precision medicine, biomechanical microenvironment, cancer immune evasion, human tissue samples.